Doubling down on the PI3k-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness

Neoplasia (United States)

Volumn 16, Issue 1, 2014, Pages 43-72

  De, Pradip ^a,b   Sun, Yuling ^a   Carlson, Jennifer H ^a   Friedman, Lori S ^c   Leyland Jones, Brian R ^a,b   Dey, Nandini ^a,b  

^a Avera Health   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE; APITOLISIB; BETA ACTIN; BH3 PROTEIN; CARBOPLATIN; CASPASE 3; CASPASE 9; CD31 ANTIGEN; KI 67 ANTIGEN; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; VASCULOTROPIN RECEPTOR; VELIPARIB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CHEMICAL ANALYSIS; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA DAMAGE; GENE DUPLICATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; CARBOPLATIN; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, BRCA2; HUMANS; KI-67 ANTIGEN; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; TOR SERINE-THREONINE KINASES; TRIPLE NEGATIVE BREAST NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84900421919     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.131694     Document Type: Article

References (61)

1. Grigoriadis A, Mackay A, Noel E, Wu PJ, Natrajan R, Frankum J, Reis-Filho JS, and Tutt A (2012). Molecular characterisation of cell line models for triplenegative breast cancers. BMC Genomics 13, 619.
2. Boyle P (2012). Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 23(suppl 6), vi7-vi12.
3. de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, and Tjan-Heijnen VC (2011). Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 137, 183-192.
4. Martins FC, De S, Almendro V, Gönen M, Park SY, Blum JL, Herlihy W, Ethington G, Schnitt SJ, Tung N, et al. (2012). Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov 2, 503-511.
5. Dey N, Smith BR, and Leyland-Jones B (2012). Targeting basal-like breast cancers. Curr Drug Targets 13, 1510-1524.
6. Jones N, Bonnet F, Sfar S, Lafitte M, Lafon D, Sierankowski G, Brouste V, Banneau G, Tunon de Lara C, Debled M, et al. (2013). Comprehensive analysis of PTEN status in breast carcinomas. Int J Cancer 133, 323-334.
7. Mao Z, Jiang Y, Liu X, Seluanov A, and Gorbunova V (2009). DNA repair by homologous recombination, but not by nonhomologous end joining, is elevated in breast cancer cells. Neoplasia 11, 683-691.
8. Pal SK, Childs BH, and Pegram M (2011). Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125, 627-636.
9. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. (2010). Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376, 235-244.
10. Gartner EM, Burger AM, and Lorusso PM (2010). Poly(ADP-ribose) polymerase inhibitors: a novel drug class with a promising future. Cancer J 16, 83-90.
11. Tutt A, Robson M, Garber JE, Domchek S, Audeh MW, Weitzel JN, Friedlander M, and Carmichael J (2009). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol (Meet Abstr) 27, CRA501.
12. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921.
13. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et al. (2009). Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361, 123-134.
14. Daemen A, Wolf DM, Korkola JE, Griffith OL, Frankum JR, Brough R, Jakkula LR, Wang NJ, Natrajan R, Reis-Filho JS, et al. (2012). Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib. Breast Cancer Res Treat 135, 505-517.
15. Kumar A, Fernandez-Capetillo O, and Carrera AC (2010). Nuclear phosphoinositide 3-kinase β controls double-strand break DNA repair. Proc Natl Acad Sci USA 107, 7491-7496.
16. Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmana J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, et al. (2012). Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2, 1048-1063.
17. Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzmán M, Grueso J, et al. (2012). PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2, 1036-1047.
18. Keith CT and Schreiber SL (1995). PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science 270, 50-51.
19. Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, O'Reilly T, Natt F, Hall J, Lane HA, and Thomas G (2005). The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120, 747-759.
20. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, and Thomas G (2001). Mammalian TOR: a homeostatic ATP sensor. Science 294, 1102-1105.
21. Hay N and Sonenberg N (2004). Upstream and downstream of mTOR. Genes Dev 18, 1926-1945.
22. De P, Miskimins K, Dey N, and Leyland-Jones B (2013). Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope. Cancer Treat Rev 39, 403-412.
23. Mukherjee B, Tomimatsu N, Amancherla K, Camacho CV, Pichamoorthy N, and Burma S (2012). The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia 14, 34-43.
24. Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, Shen Y, Mills GB, Minna JD, Heymach JV, et al. (2013). Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res 19, 6322-6328.
25. Herold CI and Anders CK (2013). New targets for triple-negative breast cancer. Oncology 27, 846-854.
26. Dey N, Barwick B, Moreno C, Ordanic-Kodani M, Chen Z, De P, Tang W, Catzavelos C, Kerstann K, Sledge GW, et al. (2013). Wnt signaling in triple negative breast cancer is associated with poor prognosis and metastasis. BMC Cancer 27. DOI: 10.1186/1471-2407-13-537, E-pub ahead of print.
27. Dey N, Young B, Abramovitz M, Bouzyk M, Barwick B, De P, and Leyland- Jones B (2013). Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner. PLoS One 8, e77425.
28. Dey N, De PK, Wang M, Zhang H, Dobrota EA, Robertson KA, and Durden DL (2007). CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiation. Mol Cell Biol 27, 4179-4197.
29. Dey N, Howell BW, De PK, and Durden DL (2005). CSK negatively regulates nerve growth factor induced neural differentiation and augments AKT kinase activity. Exp Cell Res 307, 1-14.
30. Lee GY, Kenny PA, Lee EH, and Bissell MJ (2007). Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4, 359-365.
31. Sun Y, Dey N, Brammer M, De P, and Leyland-Jones B (2013). Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab-refractory breast cancer model. Cancer Chemother Pharmacol 72, 733-745.
32. Chen H, Ma Z, Vanderwaal RP, Feng Z, Gonzalez-Suarez I, Wang S, Zhang J, Roti Roti JL, Gonzalo S, and Zhang J (2011). The mTOR inhibitor rapamycin suppresses DNA double-strand break repair. Radiat Res 175, 214-224.
33. Ma W, Halweg CJ, Menendez D, and Resnick MA (2012). Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus. Proc Natl Acad Sci USA 109, 6590-6595.
34. Burma S, Chen BP, Murphy M, Kurimasa A, and Chen DJ (2001). ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 276, 42462-42467.
35. Hans MA, Müller M, Meyer-Ficca M, Bürkle A, and Küpper JH (1999). Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: evidence for increased tumor cell apoptosis in vivo. Oncogene 18, 7010-7015.
36. Graeser M, McCarthy A, Lord CJ, Savage K, Hills M, Salter J, Orr N, Parton M, Smith IE, Reis-Filho JS, et al. (2010). A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 16, 6159-6168.
37. Yang SX, Kummar S, Steinberg SM, Murgo AJ, Gutierrez M, Rubinstein L, Nguyen D, Kaur G, Chen AP, Giranda VL, et al. (2009). Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Ther 8, 2004-2009.
38. Bryant HE and Helleday T (2006). Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res 34, 1685-1691.
39. Kamel D, Brady B, Tabchy A, Mills GB, and Hennessy B (2012). Proteomic classification of breast cancer. Curr Drug Targets 13, 1495-1509.
40. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870.
41. Montoni A, Robu M, Pouliot E, and Shah GM (2013). Resistance to PARPinhibitors in cancer therapy. Front Pharmacol 4, 18.
42. Sutherlin DP, Bao L, Berry M, Castanedo G, Chuckowree I, Dotson J, Folks A, Friedman L, Goldsmith R, Gunzner J, et al. (2011). Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/ mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. J Med Chem 54, 7579-7587.
43. Upadhyay D, Bundesmann M, Panduri V, Correa-Meyer E, and Kamp DW (2004). Fibroblast growth factor-10 attenuates H2O2-induced alveolar epithelial cell DNA damage: role of MAPK activation and DNA repair. Am J Respir Cell Mol Biol 31, 107-113.
44. Weidhaas JB, Eisenmann DM, Holub JM, and Nallur SV (2006). A conserved RAS/mitogen-activated protein kinase pathway regulates DNA damage-induced cell death postirradiation in Radelegans. Cancer Res 66, 10434-10438.
45. Cho HJ, Jeong HG, Lee JS, Woo ER, Hyun JW, Chung MH, and You HJ (2002). Oncogenic H-Ras enhances DNA repair through the Ras/phosphatidylinositol 3-kinase/Rac1 pathway in NIH3T3 cells. Evidence for association with reactive oxygen species. J Biol Chem 277, 19358-19366.
46. Lee-Kwon W, Park D, and Bernier M (1998). Involvement of the Ras/extracellular signal-regulated kinase signalling pathway in the regulation of ERCC-1 mRNA levels by insulin. Biochem J 331(pt 2), 591-597.
47. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P, and Hagan MP (2003). Epidermal growth factor and ionizing radiation up-regulate the DNA repair genes XRCC1 and ERCC1 in DU145 and LNCaP prostate carcinoma through MAPK signaling. Radiat Res 159, 439-452.
48. Shintani S, Li C, Mihara M, Terakado N, Yano J, Nakashiro K, and Hamakawa H (2003). Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 107, 1030-1037.
49. McKenna WG, Weiss MC, Endlich B, Ling CC, Bakanauskas VJ, Kelsten ML, and Muschel RJ (1990). Synergistic effect of the v-myc oncogene with H-ras on radioresistance. Cancer Res 50, 97-102.
50. Sklar MD (1988). The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 239, 645-647.
51. Saal LH, Gruvberger-Saal SK, Persson C, Lövgren K, Jumppanen M, Staaf J, Jönsson G, Pires MM, Maurer M, Holm K, et al. (2008). Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 40, 102-107.
52. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, and Yin Y (2007). Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128, 157-170.
53. Baker SJ (2007). PTEN enters the nuclear age. Cell 128, 25-28.
54. Minami D, Takigawa N, Takeda H, Takata M, Ochi N, Ichihara E, Hisamoto A, Hotta K, Tanimoto M, and Kiura K (2013). Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol Cancer Res 11, 140-148.
55. Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70.
56. Natarajan S, Hombach-Klonisch S, Droge P, and Klonisch T (2013). HMGA2 inhibits apoptosis through interaction with ATR-CHK1 signaling complex in human cancer cells. Neoplasia 15, 263-280.
57. Wallin JJ, Edgar KA, Guan J, Berry M, Prior WW, Lee L, Lesnick JD, Lewis C, Nonomiya J, Pang J, et al. (2011). GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol Cancer Ther 10, 2426-2436.
58. Lee SJ, Lee SH, Yoon MH, and Park BJ (2013). A new p53 target gene, RKIP, is essential for DNA damage-induced cellular senescence and suppression of ERK activation. Neoplasia 15, 727-737.
59. Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, and Arteaga CL (2012). Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA 109, 2718-2723.
60. Yi YW, Hong W, Kang HJ, Kim HJ, Zhao W, Wang A, Seong YS, and Bae I (2013). Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells. J Cell Mol Med 17, 648-656.
61. Vijapurkar U, Robillard L, Zhou S, Degtyarev M, Lin K, Truong T, Tremayne J, Ross LB, Pei Z, Friedman LS, et al. (2012). mTOR kinase inhibitor potentiates apoptosis of PI3K and MEK inhibitors in diagnostically defined subpopulations. Cancer Lett 326, 168-175.